Maximising Patient Engagement in Clinical Trials
Elevating Drug Safety
Why Sustainable Biomanufacturing Must Start Earlier in The Process
Clinically Validated Probiotics
Electronic Logs - The next phase of execution maturity in pharma
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Takeda Pharmaceutical Company Limited
Chief Medical & Scientific Officer
Scientific progress depends upon collaboration iPS cell technology is at the forefront of pharmaceutical innovation and Takeda strives to bring innovative treatments to patients Both Takeda and CiRA have the common goal of providing patients and healthcare professionals with innovative new treatments
Articles
Analysis of Blood Microbiota Compositionin Cardiovascular Disease Patients
Cardiovascular diseases CVDs are now the leading cause of morbidity and mortality worldwide Khan et al Despite substantial breakthroughs in prevention fast detection and treatment CVDs continue to place a significant socioeconomic burden on health systems and communities CVDs prevalence has risen by and mortality has risen by accounting for more
Research Insights
Isolation of Salivary Cell-free DNA for Cancer Detection
Saliva is an emerging source of disease biomarkers particularly for cancers of the head and neck Although analysis of cellfree DNA cfDNA in saliva holds promise as a liquid biopsy for cancer detection currently there are no standardized methodologies for the collection and isolation of saliva for the purposes of studying DNA
Case Studies
Open Innovation in Pharmaceutical Industry: A Case Study by Eli Lilly
Abstract Interest on Open Innovation paradigm has seen a phenomenal increase since last two decades especially when Henry Chesbrough coined this term in triggering the creation of a new whole body of knowledge However all of his research work could not come up with a standardized allinone theory Instead we find a heterogeneous series of models tha
Techno Trends
Celltrion Developed First-of-its-kind ZYMFENTRA™ for the Treatment of Crohn's Disease
Celltrion has developed firstofitskind ZYMFENTRA a pioneering subcutaneous formulation of infliximab
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Unleashing the Power of Data, Collaboration, and Innovation in Drug Development
Pooja is a Healthcare & Life Sciences leader at Thoughtworks with over 15 years of experience in technology consulting. Specialising in AI-driven solutions and strategic initiatives that enhance drug discovery and patient care, she has a unique background in both bioinformatics and product management. Passionate about navigating ambiguity and solving customer problems, Pooja’s current focus is on leveraging emerging technologies to accelerate innovation in healthcare and life sciences.
Emerging Technologies in Pharmaceutical Sciences
Abhishek Rungta is the Founder and CEO of INT. (Indus Net Technologies), a full-stack digital transformation company serving 500+ enterprise clients across 45 countries. He writes on enterprise AI adoption, digital transformation, and long-term business building.
The Transformative Impact of AI on Regulatory Affairs
Yu Han, DPhil in Engineering Science from the University of Oxford, brings a rich background with experience at manufacturer, global regulatory affairs CRO, and AI sector. Her expertise spans the regulatory landscapes of Asia, the US, and the EU, providing a comprehensive understanding of global pharmaceutical regulations. Passionate about combining AI technology with healthcare, Yu excels in creating innovative engineering tools to advance medical solutions. Her work leverages engineering methodologies to unravel complexities in the medical listing process, streamlining the global product flow.
<p> </p>
Email: yu.han@eng.ox.ac.uk
Architecting the Modern MICC for Life Sciences GCCs
Tanshuman Das is a life sciences technology and commercial leader with 17+ years of experience across pharmacovigilance, AI, CRO services and drug safety technology. He leads Sales & Marketing at Synapmed and focuses on translating AI and intelligent automation into practical, scalable solutions for life sciences organisations.
Alpha-fetoprotein as a Shuttle for Medicines
Vladimir Pak received his Ph.D. from the Institute of Bioorganic Chemistry, Moscow. He modernized technologies and manufactured APIs for the known drugs. Invented anticancer drug candidates based on alpha-fetoprotein that can be used as injectable or orally. Developed supplements to treat stomach ulcers and IBD.
press releasesRead more...
Roche opens up new possibilities for genomic research in Asia Pacific with next-generation sequencing technology
Roche is advancing its nextgeneration sequencing NGS ambitions in Asia Pacific following the global launch of AXELIOS in June Building on early adoption in South Korea Roche will bring the transformative technology closer to researchers and laboratory leaders across the region through AXELIOS Days
Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses
Charles River Laboratories International Inc announced today that it has entered into definitive agreements to acquire Frontage Holdings Corporations bioanalysis and DMPK operations in Exton Pennsylvania for approximately million in cash subject to customary closing adjustments In addition to the i...
Sino Biological Advances AI-Designed Molecule Validation with 4RISETM
AI can generate protein candidates at an unprecedented speed but experimental validation remains essential to determine whether they properly express bind targets and demonstrate the desired biological properties Sino Biological Inc Shenzhen Stock Exchange SZ a global leader in recombinant protein t...
Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery
Chai Discovery the AI company building a computeraided design suite for proteinbased therapeutics today announced a collaboration with Roche to use Chais AI models and platform in a number of drug discovery programs across its therapeutic areas
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED China Limited announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia AIHA Sovleplenib is a novel selective oral spleen tyrosine kinase Syk inhibitor
EventsRead more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 25
Nov 2026BioPharma Deals - The Survival Series
Munich, Germany
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
LATEST NEWSRead more...
IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours
IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...
Bayer’s Asundexian Receives Approval for Secondary Stroke Prevention
Bayer has received approval from the US Food and Drug Administration FDA for asundexian mg tablets marketed under the brand name Sunharbo to reduce the risk of recurrent stroke in adults following a recent noncardioembolic ischaemic stroke or highrisk transient ischaemic attack TIA
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
MindWalk Partners with Teva to Support Antibody Discovery Using AI
MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology
CStone Enters into Collaboration with Kimia Therapeutics to Advance Clinical Development of Novel Oncology Drug
CStone Pharmaceuticals has entered into a clinical development collaboration with USbased Kimia Therapeutics to advance a potential firstinclass drug candidate targeting the DNA damage response DDR pathway which plays an important role in the survival of solid tumour cells
